Sugi Predict

Sugi Predict / Targets / MGAM

MGAM

Maltase-glucoamylase · O43451 · MGAM on Sugi Atlas →

95,359 patent compounds predicted against MGAM, 55,194 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Voglibose Voglibose (SCHEMBL5882) 1.00 18/20
SCHEMBL110724 SCHEMBL110724 0.53 15/20
SCHEMBL159015 SCHEMBL159015 0.52 15/20
SCHEMBL170673 SCHEMBL170673 0.71 9/20
Camiglibose Camiglibose (SCHEMBL37446) 0.49 8/20
SCHEMBL124191 SCHEMBL124191 0.59 7/20
SCHEMBL108954 SCHEMBL108954 0.57 7/20
Acarbose Acarbose (SCHEMBL16848) 1.00 6/20
Acarbose Acarbose (SCHEMBL16849) 1.00 6/20
SCHEMBL45441 SCHEMBL45441 0.64 6/20
Validamycin A Validamycin A (SCHEMBL22760) 0.56 6/20
Validamycin A Validamycin A (SCHEMBL22761) 0.56 6/20
SCHEMBL37609 SCHEMBL37609 0.48 6/20
SCHEMBL37608 SCHEMBL37608 0.47 6/20
SCHEMBL37629 SCHEMBL37629 0.45 6/20
Inositol Inositol (SCHEMBL5831) 0.33 6/20
Scyllitol Scyllitol (SCHEMBL5832) 0.33 6/20
Scyllitol Scyllitol (SCHEMBL5969) 0.33 6/20
Nojirimycin Nojirimycin (SCHEMBL140917) 0.74 5/20
SCHEMBL94134 SCHEMBL94134 0.60 5/20

Clinical trials — most relevant to MGAM by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment PHASE4COMPLETED
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease PHASE4COMPLETED
High Dose or High Dose Frequency Study of Alglucosidase Alfa PHASE4COMPLETED
Effect of Dapagliflozin on Glycemic Variability PHASE4COMPLETED
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD PHASE4RECRUITING
A Prospective, Open Label Study of CERtican in KIdney Transplantation PHASE4COMPLETED
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12 PHASE3COMPLETED
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease PHASE3COMPLETED
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa PHASE3ACTIVE_NOT_RECRUITING
The Role of SGLT2i in Management of Moderate AS PHASE2/PHASE3UNKNOWN
Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder PHASE2RECRUITING
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients PHASE2ENROLLING_BY_INVITATION
A Double-Blind, Placebo-Controlled Study of Fermented Deglycyrrhizinated Licorice Extract PHASE2COMPLETED
A Study of rhGAA in Patients With Late-Onset Pompe Disease PHASE2COMPLETED
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG PHASE2COMPLETED
Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects PHASE1COMPLETED
A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced PHASE1COMPLETED
Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 PHASE1COMPLETED
A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher Disease EARLY_PHASE1ACTIVE_NOT_RECRUITING
Biomarker for Glycogen Storage Diseases (BioGlycogen) nanWITHDRAWN
Effect of Lactose on Blood Lipids nanCOMPLETED
Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia nanUNKNOWN
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption nanUNKNOWN
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB nanCOMPLETED
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Biomarker for Pompe Disease (BioPompe) nanWITHDRAWN
Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study) nanCOMPLETED
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease nanAPPROVED_FOR_MARKETING
Glycosade v UCCS in the Dietary Management of Hepatic GSD nanCOMPLETED
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MGAM binder may also engage these)

ProteinNameSimilarity
SI Sucrase-isomaltase, intestinal 1.000 landscape →
MGAM2 Probable maltase-glucoamylase 2 (Maltase-gluc 1.000 landscape →
P23739 — 1.000 P23739 →
O62653 — 1.000 O62653 →
Q92442 — 0.996 Q92442 →
P07768 — 0.996 P07768 →
F4J6T7 — 0.996 F4J6T7 →
O04931 — 0.995 O04931 →
Q9S7Y7 — 0.993 Q9S7Y7 →
Q9US55 — 0.992 Q9US55 →
P38138 — 0.991 P38138 →
P97449 — 0.990 P97449 →
P70699 — 0.990 P70699 →
P79098 — 0.990 P79098 →
Q93324 — 0.990 Q93324 →
P07190 — 0.990 P07190 →
P28843 — 0.990 P28843 →
P15684 — 0.990 P15684 →
Q95WY5 — 0.989 Q95WY5 →
P79171 — 0.989 P79171 →
Q9VTJ4 — 0.989 Q9VTJ4 →
P50123 — 0.988 P50123 →
P14749 — 0.988 P14749 →
D4B0X3 — 0.988 D4B0X3 →
P16406 — 0.987 P16406 →
ANPEP Aminopeptidase N 0.987 landscape →
Q5AWI5 — 0.987 Q5AWI5 →
GANC Neutral alpha-glucosidase C 0.987 landscape →
P29064 — 0.987 P29064 →
P15145 — 0.986 P15145 →